Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion

International Journal of Cancer

Volumn 109, Issue 6, 2004, Pages 893-899

  Dhodapkar, Kavita M ^a,b   Cirignano, Barbara ^a   Chamian, Francesca ^a   Zagzag, David ^b   Miller, Douglas C ^b   Finlay, Jonathan L ^b   Steinman, Ralph M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD1d; Glioma; Immunotherapy; Innate immunity; Interferon

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; LIGAND;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CELL CULTURE; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; ENDOTHELIUM CELL; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

ADULT; AGED; ANTIGENS, CD1; BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALACTOSYLCERAMIDES; GLIOMA; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIGANDS; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 15444369205     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20050     Document Type: Article

References (29)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
2. Bleyer WA. Epidemiologic impact of children with brain tumors. Childs Nerv Syst 1999;15:758-63.
3. Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery 2000;46:778-91.
4. Park SH, Bendelac A. CD1-restricted T-cell responses and microbial infection. Nature 2000;406:788-92.
5. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2030;21:573-83.
6. Benlagha K, Bendelac A. CD1d-restricted mouse V alpha 14 and human V alpha 24 T cells: lymphocytes of innate immunity. Semin Immunol 2000;12:537-42.
7. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
8. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998;188:1529-34.
9. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
10. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-8.
11. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells: conductors of tumor immunity? Curr Opin Immunol 2002;14:165-71.
12. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-27.
13. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kancko Y, Koseki H, Kanno M, Taniguchi M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6.
14. + natural killer T cells using alpha galactosyl ceramide pulsed dendritic cells. J Immunol Methods 2003; 272:147-59.
15. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 2002;168:6494-9.
16. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50.
17. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173-80.
18. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
19. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-42.
20. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-36.
21. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002;195:637-41.
22. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001;167:3114-22.
23. Fujii SI, Shimuzu K, Kronenberg M, Steinman RM. Prolonged interferon-g producing NKT responses induced with a-galactosyl ceramide loaded dendritic cells. Nat Immunol 2002;3:867-74.
24. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1789-99.
25. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of Disialoganglioside GD3 to natural killer T cells. J Exp Med 2003;198:173-81.
26. Chen B, Timiryasova TM, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther 2000;7:1437-47.
27. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002;100:1728-33.
28. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
29. Shin T, Nakayama T, Akutsu Y, Motohashi S, Shibata Y, Harada M, Kamada N, Shimizu C, Shimizu E, Saito T, Ochiai T, Taniguchi M. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Valpha14 NKT cells. Int J Cancer 2001;91:523-8.